<DOC>
	<DOCNO>NCT03006159</DOCNO>
	<brief_summary>This randomize , placebo-controlled , multiple dose escalation study investigate safety , tolerability , pharmacokinetics pharmacodynamics SHR0534 . The study conduct dose 5 mg , 10mg 25 mg. Chinese Type 2 Diabetic patient randomize cohort receive study drug placebo .</brief_summary>
	<brief_title>A Phase 1 , Randomized , Placebo-controlled , Multiple Dose Escalation Study Investigate Safety , Pharmacokinetics , Pharmacodynamics SHR0534 Chinese Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<criteria>Type 2 diabetes diagnose 3 month ; HbA1c ≥7.0 ≤10.5 % naive patient , ≥6.5 ≤9.5 % patient treat single oral drug , FPG ≤13.9 mmol/L randomization ; Body Mass Index ( BMI ) 18 40 kg/m^2 ( inclusive ) total body weight least 50 kg ; Agree stop drug diabetes washout study period ; Serum C peptide concentration ≥0.8ng/mL randomization . Participated drug clinical trial within 3 month ≥3 time last year , blood donation/loss≥400mL Blood recipient within 3 month randomization ; History use Insulin within 6 month ; Drug alcohol abuse within 6 month ; Use hypoglycemic drug weight reduce drug within 3 month , use grug dietary supplement within 1 week prior screen ; Underwent surgical procedure within 1 month prior screening , plan major surgical procedure study period ; Subject refrain smoking , eat and/or drink contain xanthine/caffeine , strenuous exercise , others affect drug absorption , distribution , metabolism excretion within 2 day study drug administration ; With active hepatitis ; Uncontrolled endocrine system disease ( hyperthyroidism , hypothyroidism , Cushing syndrome , multiple endocrine neoplasia ) ; Uncontrolled hypertension systolic blood pressure ( SBP ) &gt; 160mmHg / diastolic pressure ( DBP ) &gt; 100 mmHg drug treatment ; History recurrent severe hypoglycemia ; With severe chronic gastrointestinal disease ( e.g. , active ulcer within 6 month ) treatment may affect drug absorption ( e.g. , gastrointestinal surgery ) ; With cancer ( skin basal cell carcinoma ) treat untreated within last 5 year ; History decompensated heart failure ( NYHA grade III IV ) , unstable angina , stroke transient ischemic attack , persistent myocardial infarction , clinical significance arrhythmia ( frequent contraction ) , coronary artery bypass graft percutaneous coronary intervention within 6 month ; History acute metabolic complication , proliferative retinopathy maculopathy require acute treatment within 6 month ; Severe trauma severe infection may affect glycemic control within 1 month screen ; AST , ALT TBIL＞1.5×UNL , Cre＞1.5 mg/dL ( male ) /1.4 mg/dL ( female ) , ACR &gt; 300mg/g screening ; Positive hepatitis B surface antigen , hepatitis C antibody , HIV antibody syphilis antibody ; With clinical significance abnormal ECGs , II III degree atrioventricular block ( except right bundle branch block ) , long QT syndrome QTc &gt; 500 MS ; Subject suitable study determine Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>